PRKAG2グリコゲン貯蔵性心筋病変と電気生理学的症状の可逆性
Cordula M Wolf1, Michael Arad, Ferhaan Ahmad
1Department of Cardiology, Children's Hospital Boston, Boston, MA 02115, USA.
Circulation
|December 26, 2007
まとめ
PRKAG2の変異は心臓病を引き起こす. ネズミのPRKAG2遺伝子を抑制することで,心臓機能不全や心律不整が逆転し,グリコゲン貯蔵性心筋病症の治療の可能性を示した.
科学分野:
- 心血管遺伝学 心血管遺伝学
- 分子心臓病学 分子心臓病学
- 遺伝疾患モデル 遺伝疾患モデル
背景:
- PRKAG2の変異は,グリコゲン貯蔵性心筋病症,心室前刺激,伝導系変性に関連しています.
- 病気のメカニズムと回復性を調査するには,適切な動物モデルが必要です.
研究 の 目的:
- PRKAG2に関連した心臓病の疾患メカニズムを調査する.
- マウスモデルで病気の特徴の予防性と回復性を評価する.
主な方法:
- 人間のPRKAG2cDNAを発現するマウスのバイナリ誘導性トランスジェニックシステムを利用しました.
- 様々な発達段階でのトランスゲン発現を抑制するために投与されたテトラサイクリン.
- エコーカルディオグラフィー,ECG,およびin vivo電気生理学の研究を実施しました.
主要な成果:
- 生涯トランスゲン発現 (Tg(ON)) を有するマウスは,心筋縮,膨張,心室前刺激,伝導系疾患を発症した.
- トランスゲン抑制により,心臓のグリコゲン含有量が減少しました.
- 早期の産後抑制は,副次経路の発達を防ぐが,心筋病や伝導系変性ではありません.
結論:
- PRKAG2疾患における心筋病,心臓機能障害,および電気生理学的障害は,可逆性がある.
- 早期の介入は,疾患の発現の一部を予防できるが,すべての発現を防ぐことはできない.
- 心臓のグリコゲン含有量を低下させると,グリコゲン貯蔵性心筋病気が調節される可能性があります.
関連する概念動画
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:30Cardiac Action Potential
Cardiac action potentials are essential for proper heart function, enabling the rhythmic contractions needed for adequate blood circulation. Nodal cells and Purkinje fibers, specialized for electrical conduction, generate these action potentials.
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
01:25Cardiomyopathy I: Introduction and Classification
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...